When President Trump signed an executive order to try to reduce drug prices, the pharmaceutical industry saw this as a big win, since the order said Trump’s staff would put together a report “reevaluating the role of middleman,” Josh Dawsey, Kristina Peterson, and Maggie Severns of The Wall Street Journal reports. Drugmakers spent a record $31M to lobby in Washington last year, with many executives spending time working to convince others that middlemen, or pharmacy-benefit managers, are at fault for the rising costs in the pharmaceutical industry. Pharmacy-benefit managers include CVS Health (CVS) and UnitedHealth (UNH).
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Options Volatility and Implied Earnings Moves This Week, April 29 – May 02, 2025
- Most Anticipated Earnings this Week – Week of April 28, 2025
- CVS Health Positioned for Growth: Buy Rating Affirmed Amid Earnings Recovery and Strategic Improvements
- Rite Aid Flirts With a Second Bankruptcy Filing
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue